📅 PUBMED DAILY TRIAGE — 2026-06-16
Window: 2026-06-15T09:00Z → 2026-06-16T09:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~90 candidates | Formally classified: 22 High priority: 3 | Standard: 16 | Low/archive: 3 | Unsolicited finds: 2 Run status: ✅ SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
🩸 Hematologic Malignancies
TR-2026-06-16-002 / PMID 42297916 · Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia · 8/10 · 🟠 NOVEL_TREATMENT
First systematic multi-institutional characterization of BRAF mutations in AML — Leukemia journal — directly identifies a targetable molecular vulnerability using BRAF/MEK inhibitors in a disease with critically limited precision therapy options.
TR-2026-06-16-003 / PMID 42297808 · Liposomal mitoxantrone plus tislelizumab in R/R extranodal NK/T-cell lymphoma: phase 1b/2 trial · 8/10 · 🟠 NOVEL_TREATMENT
Phase 1b/2 trial in Nature Communications — novel combination chemotherapy + PD-1 inhibitor for ENKTL, one of the most aggressive and rare lymphomas with very few second-line options.
🧬 Early Cancer Detection (Liquid Biopsy / ctDNA / cfDNA)
TR-2026-06-16-001 / PMID 42294888 · Tumor-derived cell-free DNA detected in cerebrospinal fluid enables minimally invasive profiling of pediatric brain tumors · 9/10 · 🔴 EARLY_CANCER_DETECTION
Clinical Trial in Journal of Clinical Investigation — CSF cfDNA enables minimally invasive real-time molecular profiling of pediatric brain tumors, replacing/complementing repeat surgical biopsies in one of the most treatment-refractory childhood cancer categories.
💉 Novel Therapeutics
Best from this topic is PMID 42297808 (shared with Hematologic Malignancies above, 8/10).
🤖 AI/ML in Diagnostics
No 8+ articles today. Best candidate scored 6/10 (PMID 42298142 — multi-modal AI for ovarian cancer staging).
🎯 Precision Oncology
No 8+ articles today. Best candidate scored 7/10 (PMID 42298098 — ENLIGHT AI immunotherapy predictor longitudinal validation).
❤️ Cardiovascular-Metabolic
No high-priority finds today (zero-HIGH streak: day 5). Best candidate scored 6/10 (PMID 42297539 — modifiable CVD risk factors + ACS-free survival, multicenter cohort).
🧓 Aging / Longevity
No high-priority finds today (zero-HIGH streak: day 6). Best candidate scored 5/10 (PMID 42297772 — p16INK4a/senescence-autophagy in pulmonary fibrosis, likely preclinical).
🦠 Rare Diseases
No 8+ articles today. Best candidates scored 6/10 (PMID 42297642 — pediatric monomorphic PTLD national study; PMID 42297703 — rare disease + ML implications, Lancet Digit Health).
🔬 CBC / ML in Hematology
Zero relevant candidates again. 9 raw articles reviewed — none matched CBC-specific diagnostic ML criteria.
🟢⚪ STANDARD (5–7) — Top by Topic
🩸 Hematologic Malignancies
- TR-2026-06-16-006 / PMID 42297741 · CAR-T safety in R/R MM: systematic review + meta-analysis · 7/10 · Treatment Innovation (Br J Haematol)
- TR-2026-06-16-013 / PMID 42297668 · Belantamab mafodotin PK/safety in R/R MM with renal impairment · 6/10 · Drug Development (Clin Lymphoma Myeloma Leuk)
🧬 Early Cancer Detection
- TR-2026-06-16-017 / PMID 42296145 · Parental acceptability of genomic newborn screening expansion (France, nationwide) · 5/10 · Public Health (PLoS One)
🤖 AI/ML in Diagnostics
- TR-2026-06-16-012 / PMID 42298142 · Multi-modal AI (US+CT+MR) for preoperative ovarian cancer prediction — parity with MDT consensus · 6/10 · Diagnostics (NPJ Digit Med)
- TR-2026-06-16-014 / PMID 42297703 · Precision medicine trajectory toward rare-disease-sized cohorts: implications for ML/DL · 6/10 · Diagnostics (Lancet Digit Health)
🎯 Precision Oncology
- TR-2026-06-16-004 / PMID 42298098 · Longitudinal validation of ENLIGHT AI predictor for immunotherapy response in pan-cancer cohorts · 7/10 · Diagnostics / Genomics (NPJ Precis Oncol)
- TR-2026-06-16-005 / PMID 42298141 · 3D multi-omics tumour atlases: technology to biology to clinical translation · 7/10 · Genomics (Nat Rev Cancer)
- TR-2026-06-16-015 / PMID 42298062 · WFS1 targeting overcomes KRAS G12D dependency in pancreatic cancer · 5/10 · Drug Development (NPJ Precis Oncol) — preclinical cap applied
💉 Novel Therapeutics
- TR-2026-06-16-008 / PMID 42298180 · Transcriptomic profiling identifies immunotherapy-responsive phenotypes in MSS mCRC · 7/10 · Genomics / Treatment Innovation (Oncogene)
- TR-2026-06-16-018 / PMID 42298055 · Erlotinib + bevacizumab in EGFR-amplified metastatic solid tumors (KOSMOS I/II basket trial) · 5/10 · Precision Oncology (Int J Clin Oncol)
❤️ Cardiovascular-Metabolic
- TR-2026-06-16-010 / PMID 42297539 · Standard modifiable CVD risk factors and ACS-free survival (multicenter ISACS-TC cohort) · 6/10 · Prevention (Atherosclerosis)
- TR-2026-06-16-009 / PMID 42297532 · Hematopoietic somatic mutations in atherosclerotic CVD · 6/10 · Genomics / Prevention (Atherosclerosis)
🧓 Aging / Longevity
- TR-2026-06-16-016 / PMID 42297772 · Targeting senescence-autophagy axis via p16INK4a inhibition alleviates pulmonary fibrosis · 5/10 · Drug Development (Signal Transduct Target Ther)
🦠 Rare Diseases
- TR-2026-06-16-011 / PMID 42297642 · Pediatric monomorphic PTLD: national retrospective study (Spain) · 6/10 · Other (An Pediatr)
- TR-2026-06-16-017 / PMID 42296145 · (see Early Detection above)
💡 UNSOLICITED FINDS
- PMID 42297908 · Adiposity and cancer: systematic review and meta-analysis · 7/10 · Watts EL et al., Nature Metabolism — Comprehensive meta-analysis quantifying adiposity-cancer risk across cancer types. High public health relevance. Potential pipeline hand-off for cancer prevention angle.
- PMID 42297975 · mRNA-based influenza vaccine expands the B cell response breadth in humans · 6/10 · Matz HC et al., Nature Immunology — Clinical evidence that mRNA flu vaccines broaden B cell repertoire vs. conventional vaccines. Outside watchlist (not cancer/CVD/heme); not pipeline-ready.
📊 TODAY'S BREAKDOWN
By research category:
- Treatment Innovation: 4 (042297808, 42297741, 42297916, 42297668 partial)
- Diagnostics / AI: 4 (42294888, 42298098, 42298142, 42297703)
- Genomics/Precision Medicine: 5 (42297916, 42298141, 42298180, 42298062, 42297532)
- Prevention: 2 (42297539, 42296145)
- Drug Development: 2 (42298055, 42297772)
- Public Health: 1 (42297908 unsolicited)
- Mental Health / Other: 2 (LOW)
By evidence maturity:
- Validated: 9
- Exploratory: 11
- Potentially Practice-Changing: 0
By watchlist topic (reviewed / kept ≥5 / highest score):
| Topic | Raw | Reviewed | Kept | Best Score |
|---|---|---|---|---|
| Hematologic malignancies | 106 | 10 | 4 | 8/10 ✅ |
| CBC / ML hematology | 9 | 9 | 0 | N/A ❌ streak |
| Liquid biopsy / ctDNA | 22 | 10 | 3 | 9/10 ✅ |
| AI/ML diagnostics | 185 | 10 | 3 | 6/10 |
| Precision oncology | 216 | 10 | 4 | 7/10 |
| Novel therapeutics | 206 | 10 | 4 | 8/10 ✅ |
| Cardiovascular-metabolic | 280 | 10 | 2 | 6/10 ❌ streak 5d |
| Aging / longevity | 68 | 10 | 2 | 5/10 ❌ streak 6d |
| Rare diseases | 18 | 10 | 3 | 6/10 |
| Sentinel | 1440 | 10 | 2 | 7/10 |
By source type: peer_reviewed: 22 | preprint: 0
Topics with zero 8+ articles today: AI/ML diagnostics, Precision oncology, Cardiovascular-metabolic, Aging/longevity, Rare diseases, CBC/ML hematology
🔧 RUN NOTES
- Window: 24h CRDT (2026-06-15T09:00Z → 2026-06-16T09:00Z). No expansion needed — 24h window yielded 3 HIGH articles, sufficient.
- T2 (CBC/ML hematology) — zero-relevant-signal streak continues. 9 raw results reviewed; all off-target. The query is picking up peripheral blood as a generic term. Recommended fix: Narrow query to
("CBC" OR "complete blood count" OR "hematology analyzer" OR "blood smear morphology" OR "leukocyte differential") AND (machine learning OR deep learning)— omit generic "peripheral blood." - T7 (Cardiovascular-metabolic) — zero-HIGH streak: day 5. High volume (280 raw) but dominated by GLP-1 in aesthetic/surgical contexts and narrative reviews. Core cardiometabolic RCT + outcomes literature appears sparse in the CRDT window. Monday lag not a factor today (Tuesday run).
- T8 (Aging/longevity) — zero-HIGH streak: day 6. 68 raw with
humans[MeSH]filter. Human longevity/senolytic clinical trial data remains very sparse. Recommend adding:(dasatinib OR quercetin OR fisetin OR navitoclax OR rapamycin OR metformin) AND (aging OR senescence OR longevity)as a secondary T8 query for senolytic/geroprotector trials. - Top article today: PMID 42294888 (JCI Clinical Trial — CSF cfDNA profiling in pediatric brain tumors, 9/10) — strongest single-day find in 2 weeks.
- Breakthrough alert: BRAF mutations in AML (PMID 42297916, Leukemia) — first major systematic study linking BRAF to AML therapeutics. Monitor for follow-up trials.
- Rolling 7-day zero-HIGH topics: Cardiovascular-metabolic (5 days), Aging/longevity (6 days), CBC/ML (ongoing).